Showing 11-20 of 28 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Cardiotoxic Circulating Extracellular Vesicles: New Drivers of Type 1 Diabetes-induced Cardiomyopathy | Icahn School of Medicine at Mount Sinai | Susmita Sahoo | Improving Lives | 01-April-2025 to 30-September-2026 | $199,998.24 |
| Defining antigen-presenting cell – CD8 T cell crosstalk in type 1 diabetes using uLIPSTIC | Icahn School of Medicine at Mount Sinai | Verena van der Heide | Cures | 01-May-2026 to 30-April-2029 | $600,000.00 |
| Autoimmune stem-like T cells in type 1 diabetes | Memorial Sloan-Kettering Cancer Center | Andrea Schietinger | Cures | 01-September-2023 to 31-August-2026 | $750,000.00 |
| T1D Data Identification Consensus Initiative | Milliman | Rebecca Smith | Cures | 15-September-2026 to 31-May-2027 | $260,000.00 |
| GPR75, a novel actor in beta cell regeneration | New York Medical College | Ercument Dirice | Cures | 01-April-2022 to 31-March-2027 | $750,000.00 |
| Differential Aptalyzer: a wearable hydrogel microneedle platform for continuous monitoring of C-peptide in vivo | New York University | Mahla Poudineh | Cures | 01-November-2026 to 31-October-2029 | $997,957.86 |
| Triple therapy for T1DM with insulin, semaglutide and dapagliflozin | The Research Foundation of SUNY on behalf of University at Buffalo | Paresh Dandona | Improving Lives | 01-January-2019 to 31-December-2026 | $1,808,522.70 |
| Project Tuyinza | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-April-2026 to 31-March-2029 | $643,550.00 |
| Quality, Equity & Outcomes Program | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-September-2026 to 31-August-2028 | $1,400,000.00 |
| Achieving persistent presentation of self-antigens to reestablish tolerance and prevent autoimmune diabetes | Trustees of Columbia University in the City of New York | Camillo Bechi Genzano | Cures | 01-March-2025 to 29-February-2028 | $253,647.64 |